Physician profile
Satish D Narayan
NPI 1194787200
$21,502.68
in general payments reported to CMS, 2019-2025
41 companies · $2,455 in 2025
The $2,455 reported for 2025 was more than what 91% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,252 · 2020: $996 · 2021: $1,462 · 2022: $10K · 2023: $1,802 · 2024: $2,282 · 2025: $2,455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,337 · Education: $203.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,336.76 |
| Education | $202.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $9,936.19 | 2019-2025 | Spravato, Invega Sustenna, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $2,548.40 | 2019-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $1,255.68 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $1,172.83 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Abbvie INC. | $921.53 | 2021-2025 | |
| Sunovion Pharmaceuticals INC. | $843.43 | 2019-2022 | |
| Lundbeck LLC | $800.83 | 2019-2025 | Rexulti, Abilify Asimtufii |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $559.02 | 2021-2025 | Caplyta |
| Takeda Pharmaceuticals U.S.A., INC. | $536.73 | 2019-2025 | Trintellix |
| E.R. Squibb & Sons, L.L.C. | $475.11 | 2024-2025 | Cobenfy |
| Indivior INC. | $434.44 | 2019-2025 | Sublocade, Perseris |
| Supernus Pharmaceuticals, INC. | $287.10 | 2021-2023 | Qelbree |
| Corium, LLC | $199.90 | 2021-2025 | Azstarys |
| Axsome Therapeutics, INC. | $193.61 | 2022-2025 | Auvelity, Sunosi |
| Tris Pharma INC | $167.15 | 2023-2025 | Dyanavel Xr, Onyda Xr |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vanda Pharmaceuticals INC. | $164.51 | 2020-2025 | Fanapt, Hetlioz |
| Idorsia Pharmaceuticals US INC | $127.12 | 2023 | Quviviq |
| Noven Therapeutics, LLC | $108.43 | 2023-2025 | Xelstrym, Secuado |
| Braeburn INC. | $94.84 | 2023-2025 | Brixadi |
| Neurocrine Biosciences, INC. | $88.96 | 2021-2025 | Ingrezza |
| Sage Therapeutics, LLC | $76.53 | 2023-2024 | |
| Merck Sharp & Dohme LLC | $66.17 | 2019-2022 | |
| Brainsway USA INC | $53.40 | 2019 | |
| Avanir Pharmaceuticals, INC. | $52.99 | 2019-2022 | |
| Medtronic, INC. | $37.27 | 2025 | Corevalve Evolut R |
| Orexo US, INC. | $30.10 | 2019 | |
| Arbor Pharmaceuticals, INC. | $26.56 | 2019 | |
| Adlon Therapeutics L.P. | $25.86 | 2020 | |
| Biotronik INC. | $23.19 | 2025 | Amvia Edge |
| Biogen, INC. | $22.64 | 2024 | Vumerity |
| Ironshore Pharmaceuticals INC. | $20.84 | 2023 | Jornay Pm |
| Bausch Health US, LLC | $19.77 | 2024 | Aplenzin |
| Avion Pharmaceuticals | $18.93 | 2023 | Methylphenidate Hydrochloride |
| Abbott Laboratories | $18.11 | 2023 | Proclaim |
| Novo Nordisk INC | $14.29 | 2020 | |
| Mdd US Operations, LLC | $14.00 | 2019 | |
| Jazz Pharmaceuticals INC. | $13.85 | 2020 | |
| Eisai INC. | $13.80 | 2020 | |
| Almatica Pharma LLC | $13.55 | 2022 | |
| Neos Therapeutics, LP | $13.23 | 2024 | Adzenys Xr-Odt |
| Allergan, INC. | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Satish Narayan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.